Acute kidney injury (AKI) is a clinical diagnosis guided by standard criteria based on changes in serum creatinine, urine output, or both. Severity of AKI is determined by the magnitude of increase in serum creatinine or decrease in urine output. Patients manifesting both oliguria and azotemia and those in which these impairments are persistent are more likely to have worse disease and worse outcomes. Short- and long-term outcomes are worse when patients have some stage of AKI by both criteria. New biomarkers for AKI may substantially aid in the risk assessment and evaluation of patients at risk for AKI.
Keywords: Acute kidney injury; Biomarkers; Clinical trials; Dialysis; Mortality; Renal recovery; Renal-replacement therapy.
Copyright © 2015 Elsevier Inc. All rights reserved.